A PK Study of Oraxol in Breast Cancer Patients

Breastcancer Clinical Trial

Official title:

A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04993040
• Other study ID #: KX-ORAX-CN-007
• Status: Completed
• Phase: Phase 1
• Start date: April 22, 2019
• Est. completion date: December 9, 2020

Study information

• Verified date: February 2021
• Source: Athenex, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, open-label, single-arm PK study in approximately 24 breast cancer patients for whom paclitaxel treatment is indicated.

Description:

This is a multicenter, open-label, single-arm PK study in approximately 24 breast cancer patients for whom paclitaxel treatment is indicated. The study contains 3 periods: the Screening / Baseline Period, the Treatment Period, and the Follow-up Period. A Final Visit will occur within 7 days of the last dose of study treatment. If subjects achieve stable disease (SD), partial response (PR), or complete response (CR) at the end of the Treatment Period, they may continue Oraxol treatment in a separate extension study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: December 9, 2020
• Est. primary completion date: December 9, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed written informed consent

2. Women =18 years of age on day of consent

3. Breast cancer in patients for whom treatment with IV paclitaxel at 80 mg/m2 as monotherapy has been recommended by their oncologist.

4. Measurable disease as per RECIST v1.1 criteria

5. Adequate hematological status as demonstrated by not requiring transfusion support or

granulocyte-colony stimulating factor (G-CSF) to maintain:

• Absolute neutrophil count (ANC) =1.5 x 109/L
• Platelet count =100 x 109/L
• Hemoglobin (Hgb) =9 g/dL

6. Adequate liver function as demonstrated by:

• Total bilirubin of =1.5 mg/dL
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =3 x upper limit of normal (ULN) or =5 x ULN if liver metastasis is present
• Alkaline phosphatase (ALP) =3 x ULN or =5 x ULN if bone metastasis is present
• Gamma glutamyl transferase (GGT) <10 x ULN

7. Adequate renal function as demonstrated by serum creatinine =1.5 x ULN

8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

9. Life expectancy of at least 3 months

10. Willing to fast for 6 hours before and 2 hours after Oraxol administration on all treatment days

11. Willing to abstain from alcohol consumption for 3 days before the first dose of study drug through the completion of the second inpatient PK sampling period

12. Willing to refrain from caffeine consumption for 12 hours before each inpatient dosing period (Weeks 1 and 4) through the completion of protocol-specified PK sampling for that week

13. Subjects must be postmenopausal (>12 months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or must be using effective contraception (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for 30 days after their last dose of assigned study treatment.

14. Subjects who are of childbearing potential must have a negative serum pregnancy test at Screening and within 96 hours before Week 1 dosing.

Exclusion Criteria:

1. Have not recovered to = Grade 1 toxicity from previous anticancer treatments or previous investigational products (IPs)

2. If previously treated with a taxane (paclitaxel or docetaxel) as part of anthracycline-based adjuvant chemotherapy or for metastatic disease, the subject relapsed less than 1 year following treatment

3. Subjects unable to swallow study medication in its intact form or have clinically significant malabsorption syndrome

4. Only site of metastatic disease is unmeasurable according to RECIST v1.1 criteria

5. Known CNS metastasis, including leptomeningeal involvement

6. Received IPs within 14 days or 5 half-lives of the first study dosing day, whichever is longer

7. Are currently receiving other medications intended for the treatment of their malignancy

8. Women who are pregnant or breastfeeding

9. Taking any of the following prohibited medications:

• Strong inhibitors (eg, ketoconazole) or inducers (eg, rifampin or St. John's Wort) of CYP3A4 (within 2 weeks prior to the start of dosing in the study)
• Strong inhibitors (eg, gemfibrozil) or inducers (eg, rifampin) of CYP2C8 (within 2 weeks prior to the start of dosing in the study)
• Strong P-gp inhibitors or inducers. Subjects who are taking such medications but who are otherwise eligible may be enrolled if they discontinue the medication =1 week before dosing and remain off that medication through the end of study treatment.
• An oral medication with a narrow therapeutic index known to be a P-gp substrate (eg,digoxin, dabigatran) within 24 hours prior to start of dosing in the study

10. Use of warfarin. Subjects receiving warfarin who are otherwise eligible and who may be appropriately managed with low molecular weight heparin, in the opinion of the Investigator, may be enrolled in the study provided they are switched to low molecular weight heparin at least 7 days prior to receiving study treatment.

11. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myocardial infarction within the last 6 months, unstable angina pectoris, cardiac arrhythmia, chronic pulmonary disease requiring oxygen, known bleeding disorders, or any concomitant illness or social situation that would limit compliance with study requirements

12. Known allergic reaction or intolerance to study medication components

13. Known allergic reaction or intolerance to contrast media

14. Subjects who, in the Investigator's opinion, are not suitable for participation in this study

Related Conditions & MeSH terms

• Breast Neoplasms
• Breastcancer

Intervention

Drug:
• Oraxol
HM30181 methanesulfonate monohydrate Oral paclitaxel capsules

Locations

Country	Name	City	State
China	Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Athenex, Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cmax	Plasma concentrations for paclitaxel only will be analyzed to determine the maximum observed concentration (Cmax).; Pharmacokinetic parameters will be summarized using the mean, standard deviation, median, minimum, and maximum. Summaries of PK parameters will also include the geometric mean and the coefficient of variation. Summary PK and individual timepoints will be tabulated and displayed graphically and listed for all subjects.	Week 1 (Days 1,2, 3): Predose, and at 1, 2, 3, and 4 hours postdose; Week 4 (Days 1,2,3): Predose, and at 1, 2, 3, and 4 hours postdose
Primary	Cmin	Plasma concentrations for paclitaxel only will be analyzed to determine the minimum observed concentration (Cmin).; Pharmacokinetic parameters will be summarized using the mean, standard deviation, median, minimum, and maximum. Summaries of PK parameters will also include the geometric mean and the coefficient of variation. Summary PK and individual timepoints will be tabulated and displayed graphically and listed for all subjects.	Week 1 (Days 1,2, 3): Predose, and at 1, 2, 3, and 4 hours postdose; Week 4 (Days 1,2,3): Predose, and at 1, 2, 3, and 4 hours postdose
Primary	Cavg	Plasma concentrations for paclitaxel only will be analyzed to determine the area under the curve extrapolated to infinity (AUC0-t).; Pharmacokinetic parameters will be summarized using the mean, standard deviation, median, minimum, and maximum. Summaries of PK parameters will also include the geometric mean and the coefficient of variation. Summary PK and individual timepoints will be tabulated and displayed graphically and listed for all subjects.	Week 1 (Days 1,2, 3): Predose, and at 1, 2, 3, and 4 hours postdose; Week 4 (Days 1,2,3): Predose, and at 1, 2, 3, and 4 hours postdose
Primary	AUC0-t	Plasma concentrations for paclitaxel only will be analyzed to determine the area under the curve (AUC).; Pharmacokinetic parameters will be summarized using the mean, standard deviation, median, minimum, and maximum. Summaries of PK parameters will also include the geometric mean and the coefficient of variation. Summary PK and individual timepoints will be tabulated and displayed graphically and listed for all subjects.	Week 1 (Days 1,2, 3): Predose, and at 1, 2, 3, and 4 hours postdose; Week 4 (Days 1,2,3): Predose, and at 1, 2, 3, and 4 hours postdose
Primary	AUC	Plasma concentrations for paclitaxel only will be analyzed to determine the area under the curve (AUC).; Pharmacokinetic parameters will be summarized using the mean, standard deviation, median, minimum, and maximum. Summaries of PK parameters will also include the geometric mean and the coefficient of variation. Summary PK and individual timepoints will be tabulated and displayed graphically and listed for all subjects.	Week 1 (Days 1,2, 3): Predose, and at 1, 2, 3, and 4 hours postdose; Week 4 (Days 1,2,3): Predose, and at 1, 2, 3, and 4 hours postdose
Secondary	Safety	all AEs (including for both increasing and decreasing severity) and SAEs by CTCAE v4.03	From screening until final visit (within within 7 days after last dose of study treatment)
Secondary	Tumor response rate	which is defined as the number of subjects with complete response (CR) or partial response (PR) at any post-baseline assessments by RECIST 1.1	From screening until final visit (within within 7 days after last dose of study treatment)
Secondary	Progression-free survival	Progression Free Survival (PFS) based on investigator's assessment according to RECIST 1.1	From date of dosing until the date of first documented progression or date of death from any cause, whichever came first, estimated up to 24 months
Secondary	Overall survival	OS is defined as the length of time from 1st dosing until the date of death from any cause	From date of dosing until the date of death from any cause, whichever came first, estimated up to 24 months